Newswise — PHILADELPHIA – The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, has announced Andre Nussenzweig, PhD, of the National Cancer Institute (NCI) as the recipient of the ninth annual Basser Global Prize. Nussenzweig serves as branch chief of the Laboratory of Genome Integrity in the NCI’s Center for Cancer Research.

Each year, the Basser Global Prize recognizes a leading scientist who has conceptually advanced BRCA1/2-related research. Individuals with mutations in the BRCA1 and BRCA2 genes are at an increased risk of breast, ovarian, pancreatic and other cancers.

Nussenzweig’s work on the fundamental aspects of DNA repair, replication, and genome integrity in cells has led to important discoveries that have applications for the development of biomarkers and targeted therapeutics for the treatment of BRCA-mutated cancers.

“It’s an honor to bestow this award to an esteemed researcher from the NCI who has uncovered key insights into understanding the causes of BRCA-mutated cancers and mechanisms driving treatment resistance,” said Susan M. Domchek, MD, executive director of the Basser Center for BRCA. “It’s these types of basic science discoveries that will move us closer to improved therapies for patients.”

Nussenzweig, who received his PhD in physics from Yale University, became a research fellow at Memorial Sloan-Kettering Cancer Center prior to joining the Experimental Immunology Branch at the National Institutes of Health in 1998. In 2011, Nussenzweig established a new department at NCI called the Laboratory of Genome Integrity. He is also an elected member of the European Molecular Biology Organization, a National Institutes of Health Distinguished Investigator, and a 2019 inductee into the National Academy of Medicine.

“I am extremely honored to receive this recognition from the Basser Center which has contributed so much support for BRCA-related research and improved the clinical care of patients who bear BRCA1/2 mutations,” Nussenzweig said.

Nussenzweig will give the keynote address at the 10th annual Basser Center for BRCA Scientific Symposium on May 10 and 11, 2022.

The Basser Global Prize provides $100,000 in unrestricted support of the winner's BRCA1/2-related research efforts, a Basser sculpture, and a $10,000 personal prize, which will be awarded at the symposium.

The Basser Center was established in 2012 with a $25 million gift from University of Pennsylvania alumni Mindy and Jon Gray in memory of Mindy Gray’s sister Faith Basser, who died of ovarian cancer at age 44. To date, Mindy and Jon have donated more than $55 million to the Basser Center in support of research and education to improve treatment and prevention strategies for hereditary cancers.

The Basser Global Prize was established and subsequently endowed by Shari Basser Potter and Leonard Potter.


Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.